CASE REPORT
Possibilities of using ultrasound for diagnosis of invasive pulmonary mucormycosis – A case study
More details
Hide details
1
Department of Anesthesiology and Intensive Care, Regional Specialized Hospital in Olsztyn, Poland
2
Department of General Surgery and Transplantology, Regional Specialized Hospital in Olsztyn, Poland
3
Department of Pediatric Orthopaedic and Trauma Surgery, Regional Specialized Hospital in Olsztyn, Poland
Submission date: 2016-05-23
Acceptance date: 2016-11-10
Online publication date: 2017-05-05
Publication date: 2020-03-22
Corresponding author
Paweł Grabala
Department of Pediatric Orthopaedic and Trauma Surgery, Regional Specialized Children's Hospital in Olsztyn,
Żołnierska 18A, 10-561 Olsztyn, Poland. Tel.: +48 89 675 51 13; fax: +48 775 466 324; mobile: +48 787 111 100.
Pol. Ann. Med. 2017;24(2):224-227
KEYWORDS
ABSTRACT
Introduction:
Mucormycosis is a rare but highly lethal fungal infection, usually affecting immunocompromised patients.
Aim:
To present and analyze the diagnostic capabilities of transthoracic ultrasonography in invasive pulmonary mucormycosis.
Case study:
We present a case involving a 41-year-old female patient with pneumonia complicated by multisystem organ failure, who was diagnosed with invasive pulmonary mucormycosis.
Results and discussion:
Transthoracic ultrasonography (TUS) revealed a consolidation area of heterogeneous echostructure with an abnormal air bronchogram, possibly suggestive of an invasive pulmonary fungal disorder. The presence of lesions observed with TUS was confirmed by computed tomography (CT). The final diagnosis of mucormycosis was possible after Mucor species fungi were detected in bronchoalveolar lavage culture.
Conclusions:
(1) TUS is a widely available and inexpensive diagnostic method that is characterized by the absence of adverse effects, and its applicability in the diagnosis of pulmonary disorders other than invasive fungal infections is well documented. (2) Ultrasonographic analysis of lesions facilitates differentiation between bacterial and fungal pneumonia, and the high sensitivity and specificity of the procedure compared to CT scans as a reference method supports the reliability of ultrasound scans in the diagnosis of invasive pulmonary aspergillosis (IPA). (3) The use of TUS in the diagnosis of invasive pulmonary mucormycosis appears warranted, particularly in cases when it is impossible to obtain a proven diagnosis. (4) Ultrasonographic diagnosis of invasive lung disorders, including mucormycosis, requires further studies.
CONFLICT OF INTEREST
None declared.
REFERENCES (17)
1.
Hong HL, Lee YM, Kim T, et al. Risk factors for mortality in patients with invasive mucormycosis. Infect Chemother. 2013;45(3):292–298.
2.
Mączka AM, Kowalski IM, Onichimowski D. Pulmonary rehabilitation within intensive care units exemplified by traffic collisions casualties. Pol Ann Med. 2011;18(1):66–75.
3.
Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–569.
4.
Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44(4):335–342.
5.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(suppl 1):S23–S34.
6.
Lin PC, Chang TT, Jang RC, Chiou SS. Hepatosplenic microabscesses in pediatric leukemia: a report of five cases. Kaohsiu J Med Sci. 2003;19(7):368–374.
7.
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821.
8.
Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016.
http://dx.doi.org/10.1016/j.cm... [in press].
9.
Hoffer FA, Gow K, Flynn PM, Davidoff A. Accuracy of percutaneous lung biopsy for invasive pulmonary aspergillosis. Pediatr Radiol. 2001;31(3):144–152.
10.
Gompelmann D, Heussel CP, Schuhmann M, Herth FJ. The role of diagnostic imaging in the management of invasive fungal diseases – report from an interactive workshop. Mycoses. 2011;54(suppl 1):27–31.
11.
Choo JY, Park CM, Lee HJ, Lee CH, Goo JM, Im JG. Sequential morphological changes in follow-up CT of pulmonary mucormycosis. Diagn Interv Radiol. 2014;20(1):42–46.
12.
Volpicelli G, Elbarbary M, Blaivas M, et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012;38(4):577–591.
13.
Reissig A, Kroegel C. Sonographic diagnosis and follow-up of pneumonia: a prospective study. Respiration. 2007;74(5):537–547.
14.
Panigrahi MK, Manju R, Kumar SV, Toi PC. Pulmonary mucormycosis presenting as nonresolving pneumonia in a patient with diabetes mellitus. Respir Care. 2014;59(12):e201–e205.
15.
Zhao Z, Jiang L, Xi X, et al. Prognostic value of extravascular lung water assessed with lung ultrasound score by chest sonography in patients with acute respiratory distress syndrome. BMC Pulm Med. 2015;15:98.
16.
Bass CM, Sajed DR, Adedipe AA, West TE. Pulmonary ultrasound and pulse oximetry versus chest radiography and arterial blood gas analysis for the diagnosis of acute respiratory distress syndrome: a pilot study. Crit Care. 2015;19:282.
17.
Lichtenstein DA. Lung ultrasound in the critically ill. Ann Intensive Care. 2014;4(1):1.